Close Menu

NEW YORK (360Dx) – Intended to combat the nation's opioid crisis, the "Substance Use Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act," or SUPPORT Act, passed Congress in October of last year backed by large bipartisan majorities.

An anti-kickback provision within the larger law has clinical laboratories concerned, however, as it appears to outlaw for clinical labs various business practices that are standard within the healthcare industry, such as paying sales staff on commission or placing phlebotomists in physician practices.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.